Ocular Therapeutix Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	52.04	51.95	63.72	58.44	51.49	43.52
Revenue Growth (YoY)	-12.75%	-18.47%	9.03%	13.49%	18.32%	150.08%
Cost of Revenue	6.64	6.57	5.63	5.28	4.54	4.41
Gross Profit	45.4	45.38	58.1	53.16	46.95	39.12
Selling, General & Admin	124.38	118.3	102.24	74.49	72.15	67.07
Research & Development	220.45	197.1	127.64	61.06	53.46	50.08
Total Operating Expenses	344.84	315.39	229.88	135.54	125.61	117.15
Operating Income	-299.44	-270.02	-171.78	-82.38	-78.65	-78.04
Interest Income	20.58	18.36	20.28	3.98	0.8	0.03
Interest Expense	-11.63	-11.84	-13.58	-11.34	-7.02	-6.67
Other Non-Operating Income (Expense)	-0.01	-2.44	-28.43	9	13.84	78.12
Total Non-Operating Income (Expense)	8.94	4.08	-21.73	1.65	7.62	71.48
Pretax Income	-290.5	-265.94	-193.51	-80.74	-71.04	-6.55
Net Income	-290.5	-265.94	-193.51	-80.74	-71.04	-6.55
Net Income to Common	-290.5	-265.94	-193.51	-80.74	-71.04	-6.55
Shares Outstanding (Basic)	201	187	158	80	77	76
Shares Outstanding (Diluted)	201	187	158	86	83	82
Shares Change (YoY)	19.89%	18.31%	84.90%	3.57%	0.59%	35.24%
EPS (Basic)	-1.46	-1.42	-1.22	-1.01	-0.92	-0.09
EPS (Diluted)	-1.46	-1.42	-1.22	-1.02	-0.97	-0.98
Free Cash Flow	-240.94	-216.89	-135.97	-76.32	-63.32	-66.74
Free Cash Flow Per Share	-1.20	-1.16	-0.86	-0.89	-0.77	-0.81
Gross Margin	87.24%	87.35%	91.17%	90.96%	91.18%	89.88%
Operating Margin	-575.42%	-519.75%	-269.57%	-140.96%	-152.74%	-179.31%
Profit Margin	-558.24%	-511.90%	-303.67%	-138.15%	-137.95%	-15.06%
FCF Margin	-463.02%	-417.50%	-213.37%	-130.59%	-122.96%	-153.36%
EBITDA	-294.81	-265.69	-168	-79.4	-76.55	-75.62
EBITDA Margin	-566.54%	-511.43%	-263.63%	-135.86%	-148.65%	-173.74%
EBIT	-299.44	-270.02	-171.78	-82.38	-78.65	-78.04
EBIT Margin	-575.42%	-519.75%	-269.57%	-140.96%	-152.74%	-179.31%

SEC Filings: 10-K · 10-Q